At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 38 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 16 Years to 17 Years
- Who
- All
- Number of participants
- 500
- Started
- 2025-02-17
- Last checked
- 2025-01
Plain English Summary
What is this study?
- • Testing a new treatment for attention deficit hyerpactivity disorder
- • Clinical study - 500 participants
- • Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental condition affecting 5
Who can take part?
- • Ages 16 Years to 17 Years
- • Diagnosed with attention deficit hyerpactivity disorder
Where?
- • London - King's College London
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental condition affecting 5.9% of young people. Late adolescence can be a particularly challenging period for young people with ADHD, with major life transitions, new demands and increased expectations. This vulnerable phase also coincides with the transition from child and adolescent mental health care to adult ADHD services, where new UK data show that most young people with ADHD do not successfully transfer to adult services. Therefore, many young people with ADHD do not receive appropriate interventions at a time when they may need them most. Opportunities for intervention are currently not fully realised due to both the young people's disengagement from clinical services and our limited understanding of real-world targets for more holistic interventions. The current study seeks to address these needs using remote (not in-person) measurement technology (RMT). The MRC-funded project, ART-transition, will use the ADHD Remote Technology ('ART') assessment and monitoring assessments with young people with a diagnosis of ADHD aged 16-17 and the RADAR-base mobile-health platform to which it is linked. ART consists of active (e.g. questionnaires) and passive (e.g. sleep) smartphone app monitoring. In the study, the investigators will address three questions on the transition to adulthood for individuals with ADHD: what changes take place, what predicts them, and how can the investigators prevent negative outcomes and support healthy lifestyles? The investigators will remotely monitor 250 young people with ADHD over two years. The investigators will then co-design, with young people with ADHD, a prototype for a new ADHD-transition smartphone app. Our approach focuses on giving young people with ADHD greater autonomy in how they manage their ADHD, in collaboration with their clinician, and places the emphasis on modifiable environmental factors and the prevention of negative outcomes.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 16 Years - 17 Years
- Who can join: All genders
What the study is looking for
- ✓Diagnosis of DSM-5 ADHD
- ✓Aged 16-17
- ✓Able to give agreement to take part for participation
- ✓Willing and able to complete self-reported assessments via smartphone
- ✓Willing to use either their own compatible Android phone or a study Android - phone as their only smartphone during...
See the full criteria
Where Is This Study? (1 UK site)
King's College London
London, United Kingdom
How to Get in Touch
Aislinn Bowler, PhD
Sponsor contactCONTACT